All News

Pharmacists can help to interpret HbA1c and glucose results when patients come to pick up medications and contact prescribers and/or make recommendations based off patient results.

However, psychedelic medicine has a variety of barriers, including historical perception, access challenges, legal obstacles, and ethical questions.

The indication is for adult patients with multiple myeloma who are refractory to lenalidomide and have previously received at least 1 line of therapy.

Venetoclax, which is approved for leukemia, blocks a function of the BCL-2 protein and has previously shown efficacy in a small proportion of patients with multiple myeloma.

In a review, investigators focused on ranibizumab (Lucentis; Genentech), aflibercept (Eylea; Regeneron), and bevacizumab (Avastin; Genentech) as growth opportunities in the biosimilar space.

Investigators found that older adults, adults with dementia, and adults with altered mental status were more likely to be inappropriately diagnosed with CAP when hospitalized.

Pharmacists should be well educated on prescription digital therapeutics to better educate patients on software in comparison to traditional pharmacological products.

Pharmacists can address social determinants to improve patient well-being and treatment.

Challenges in treating insomnia in special groups and resistant cases, and ways for pharmacists to improve outcomes.

Social determinants of health can worsen mental health disorders such as depression, but the effect of depression can also negatively impact social determinants of health.

Piezo1 is a protein produced by type 2 innate lymphoid cells when activated by an allergen and can limit the immune cell’s activity when triggered by a reaction.

In March 2024, the label for bempedoic acid was expanded to reduce cardiovascular risk and expand the low-density lipoprotein-C (LDL-C) lowering in both primary and secondary prevention patients.

Potential for integration into care and future advancements for gaps in current schizophrenia treatments

Current evidence and data regarding clozapine-resistant schizophrenia is unclear, but new treatment options are on the horizon that could show promise.

Guidance on evaluating contraceptive options for patients with psychiatric conditions

Although there are medical considerations for patients with psychiatric conditions, prescribers must consider patient preference to increase adherence and effectiveness of contraception.

The treatment is indicated for adolescents at least 12 years of age who weigh at least 25 kg without a previous treatment history of antiretroviral therapies.

The finding did not reach statistical significance in the primary composite endpoint.

New approaches for treating all schizophrenia symptoms by modulating dopamine and glutamate in non-traditional ways.

Aged mice displayed improvements in their spatial cognition, short-term memory, and muscle durability.

Investigators reported a low incidence of adverse events after simultaneous vaccination against seasonal influenza and respiratory syncytial virus.

Data for generalized anxiety disorders and cannabis use is scarce, but pharmacists can help educate patients on potential benefits and risks of cannabis usage.

Expert perspective on current research, treatment approaches, and clinical considerations for pharmacologic management of borderline personality disorder

Potential adjunctive and novel treatment options based on a patient's specific symptoms and clinical factors are being explored to treat treatment-resistant schizophrenia

The abstracts will be presented at the American College of Cardiology Conference from April 6 to April 8, 2024, in Atlanta, Georgia.

Developments in glycine transporter type 1 inhibitors, D-amino acid oxidase inhibitors, and phosphodiesterase inhibitors are pushing schizophrenia research forward.

The results further confirm earlier findings from the EMPA-KIDNEY trial.

Although the number of clinical trials has quadrupled, the number of FDA approvals remains stable over a 10-year period, highlighting workforce challenges in clinical research.